AVBP Latest Press Releases

-- May 11, 2026 --

ArriVent BioPharma Reports First Quarter 2026 Financial Results Globe Newswire 4:01 PM

-- May 7, 2026 --

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers Globe Newswire 8:00 AM

-- March 17, 2026 --

Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA and AQUALINK Platforms at AACR 2026 Business Wire 5:11 PM

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting Globe Newswire 5:11 PM

-- March 5, 2026 --

ArriVent BioPharma Reports Full Year 2025 Financial Results Globe Newswire 4:01 PM

-- February 11, 2026 --

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software